Intersect ENT Reports Fourth Quarter and Full Year 2016 Results

16:05 EST 28 Feb 2017 | Businesswire

This article has expired, however you can still download the PDF.
Q4 2016 Revenue Increased 29% with Gross Margin of 84% Full Year 2016 Revenue Increased 28% with Gross Margin of 83% Intersect ENT, Inc. (NASDAQ:XENT), a company dedicated to improving the quality of life for patien...

Other Sources for this Article

Intersect ENT, Inc.
Jeri Hilleman, 650-641-2105


More From BioPortfolio on "Intersect ENT Reports Fourth Quarter and Full Year 2016 Results"

Quick Search


Relevant Topics

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Clinical Approvals
Clinical trials are a set of procedures in medical research conducted to allow safety (or more specifically, information about adverse drug reactions and adverse effects of other treatments) and efficacy data to be collected for health interventions (e.g...